75 search results for: asthma

Exploring the Mechanisms of FeNO Production in the Lungs
Pulmonology
Exploring the Mechanisms of FeNO Production in the Lungs
videoanimation

Explore how type 2 inflammation drives the production of FeNO in severe asthma

View more
EventsOnDemand AAAAI2023
Congress
25
February
2023
Congress
American Academy of Allergy, Asthma, & Immunology (AAAAI) 2023 | San Antonio

Watch highlights from the AAAAI 2023 Conference in San Antonio, TX, USA.

Type 2 <b>Asthma</b> Learning Hub
Learning Hub
Type 2 Asthma Learning Hub

Type 2 asthma is a common phenotype of asthma, characterized by key cytokines IL-4, IL-13, and IL-5, as well as elevated type 2 inflammatory biomarkers as FeNO, and eosinophils, or the need for maintenance OCS. Type 2 inflammation is evident in up to 88% of patients with severe asthma, representing a substantial portion of the disease burden associated with asthma. Explore the resources below better understand the role of type 2 inflammation in asthma.

Clinical Manifestations Associated With Airway Remodeling in <b>Asthma</b>
Type 2 Inflammation
Clinical Manifestations Associated With Airway Remodeling in Asthma
expert video

Join Dr. Hanania to understand how to identify patients at risk of fixed airway obstruction in clinical settings.

View more
Dr. Giorgio Canonica Regarding Multidisciplinary Approach
Rhinology
Dr. Giorgio Canonica Regarding Multidisciplinary Approach
expert video

This video clip from the EAACI 2024 symposium highlights that a multidisciplinary approach is essential for the treatment of asthma.

View more
ERS 2024 | Can Biologics Affect Airway Remodeling?
Pulmonology
ERS 2024 | Can Biologics Affect Airway Remodeling?
expert video

Dr Mario Castro presents the latest clinical data on biologics showcasing their effect on airway remodeling parameters and airway hyperresponsiveness in patients with severe asthma.

View more
ERS 2024 | Fireside Chat: What Is the Potential for Disease Modification in the Era of Biologics?
Pulmonology
ERS 2024 | Fireside Chat: What Is the Potential for Disease Modification in the Era of Biologics?
expert video

Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss disease modification in severe asthma, including what disease modification is, how it can be identified, and how the advent of biologics may bring about disease modification.

View more
ADVENT at ERS 2024
Congress
7
September
2024
Congress
ADVENT at ERS 2024

The ADVENT program will present four symposia sharing the latest science in asthma and COPD at the 2024 European Respiratory Society (ERS) Congress. Visit Booth #A4.02 to learn more about ADVENT.

Celeste Porsbjerg
Expert
Celeste Porsbjerg, MD, PhD

Professor of Severe Asthma, Bispebjerg Hospital Copenhagen, Denmark

Nicole Chase
Expert
Nicole Chase, MD

Associate Professor of Medicine, University of Minnesota; Physician Minneapolis VA Health Care System; Partner, St. Paul Allergy & Asthma, PA

Simon Couillard
Expert
Simon Couillard, MD, MSc

Professor Couillard is a respirologist and the Québec Lung Association Chair of Respiratory Research at the Université de Sherbrooke, Canada. He leads a team investigating ways to use biomarkers to predict and prevent asthma attacks and improve asthma management.

Njira Lugogo
Expert
Njira Lugogo, MD

Dr. Lugogo is a Professor of Medicine in the Division of Pulmonary, Critical Care Medicine and is the Director of the Michigan Medicine Asthma Program. She is also the Program Director of INHALE, a statewide collaborative quality improvement program that focuses on improving the care of patients with asthma and COPD in Michigan.